EUVIMEDEUVIMED entdecken
Open Access

Efficacy of mRNA-1273 and Novavax ancestral or BA.1 spike booster vaccines against SARS-CoV-2 BA.5 infection in nonhuman primates

Nanda Kishore Routhu iD, Samuel David Stampfer iD, Lilin Lai, Akil Akhtar iD, Xin Tong, Dansu Yuan iD, Taras M Chicz iD, Ryan P McNamara iD, Kishor Jakkala, Meredith E Davis-Gardner iD, E Lovisa St Pierre, Brandon Smith iD und 16 weitere

Science Immunology · 2023

DOI: 10.1126/sciimmunol.adg7015 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Immunology, 2023. Verfasst von Nanda Kishore Routhu und 27 weiteren Autor:innen. Beteiligte Einrichtung: Division of Microbiology and Immunology, Emory Vaccine Center, Emory National Primate Research Center, Emory University, Atlanta, GA 30329, USA. Hauptthemen laut MEDLINE: 2019-nCoV Vaccine mRNA-1273, COVID-19. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH HHS, NIAID NIH HHS, NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Omicron SARS-CoV-2 variants escape vaccine-induced neutralizing antibodies and cause nearly all current COVID-19 cases. Here, we compared the efficacy of three booster vaccines against Omicron BA.5 challenge in rhesus macaques: mRNA-1273, the Novavax ancestral spike protein vaccine (NVX-CoV2373), or Omicron BA.1 spike protein version (NVX-CoV2515). All three booster vaccines induced a strong BA.1 cross-reactive binding antibody and changed immunoglobulin G (Ig) dominance from IgG1 to IgG4 in the serum. All three booster vaccines also induced strong and comparable neutralizing antibody responses against multiple variants of concern, including BA.5 and BQ.1.1, along with long-lived plasma cells in the bone marrow. The ratio of BA.1 to WA-1 spike–specific antibody-secreting cells in the blood was higher in NVX-CoV2515 animals compared with NVX-CoV2373 animals, suggesting a better recall of BA.1-specific memory B cells by the BA.1 spike–specific vaccine compared with the ancestral spike–specific vaccine. Further, all three booster vaccines induced low levels of spike-specific CD4 but not CD8 T cell responses in the blood. After challenge with SARS-CoV-2 BA.5 variant, all three vaccines showed strong protection in the lungs and controlled virus replication in the nasopharynx. In addition, both Novavax vaccines blunted viral replication in nasopharynx at day 2. The protection against SARS-CoV-2 BA.5 infection in the upper respiratory airways correlated with binding, neutralizing, and ADNP activities of the serum antibody. These data have important implications for COVID-19 vaccine development, because vaccines that lower nasopharyngeal virus may help to reduce transmission.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

2019-nCoV Vaccine mRNA-1273COVID-19AnimalsHumansCOVID-19 VaccinesMacaca mulattaSARS-CoV-2Spike Glycoprotein, CoronavirusImmunoglobulin G

Substanzen

2019-nCoV Vaccine mRNA-1273COVID-19 VaccinesSpike Glycoprotein, CoronavirusImmunoglobulin Gspike protein, SARS-CoV-2

Autor:innen und Institutionen

  • Division of Microbiology and Immunology, Emory Vaccine Center, Emory National Primate Research Center, Emory University, Atlanta, GA 30329, USA.
  • Department of Microbiology and Immunology, Emory School of Medicine, Emory University, Atlanta, GA 30322, USA.
  • Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA.
  • Emory Vaccine Center, Division of Microbiology and Immunology, Emory National Primate Research Center, Emory University, Atlanta, GA 30329, USA.
  • Division of Infectious Diseases, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA.
  • Emory Vaccine Center, Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA 30329, USA.

ORCID-Profile: Nanda Kishore Routhu, Samuel David Stampfer, Akil Akhtar, Dansu Yuan, Taras M Chicz, Ryan P McNamara, Meredith E Davis-Gardner, Brandon Smith, Kristyn Moore Green, Nadia Golden, Sherrie M Jean, Jennifer Wood, Joyce Cohen, Ian N Moore, Greg Glenn, Galit Alter, Rafi Ahmed, Mehul S Suthar, Rama Rao Amara

Förderung

  • NIH HHS
  • NIAID NIH HHS
  • NCATS NIH HHS

Zitieren

APA

Routhu, N. K., Stampfer, S. D., Lai, L., Akhtar, A., Tong, X., Yuan, D., Chicz, T. M., McNamara, R. P., Jakkala, K., Davis-Gardner, M. E., St Pierre, E. L., Smith, B., Green, K. M., Golden, N., Picou, B., Jean, S. M., Wood, J., Cohen, J., Moore, I. N., …, & Amara, R. R. (2023). Efficacy of mRNA-1273 and Novavax ancestral or BA.1 spike booster vaccines against SARS-CoV-2 BA.5 infection in nonhuman primates. Science Immunology. https://doi.org/10.1126/sciimmunol.adg7015

Vancouver

Routhu NK, Stampfer SD, Lai L, Akhtar A, Tong X, Yuan D, et al. Efficacy of mRNA-1273 and Novavax ancestral or BA.1 spike booster vaccines against SARS-CoV-2 BA.5 infection in nonhuman primates. Science Immunology. 2023. doi:10.1126/sciimmunol.adg7015

BibTeX
@article{Routhu2023,
  author = {Routhu, Nanda Kishore and Stampfer, Samuel David and Lai, Lilin and Akhtar, Akil and Tong, Xin and Yuan, Dansu and Chicz, Taras M and McNamara, Ryan P and Jakkala, Kishor and Davis-Gardner, Meredith E and St Pierre, E Lovisa and Smith, Brandon and Green, Kristyn Moore and Golden, Nadia and Picou, Breanna and Jean, Sherrie M and Wood, Jennifer and Cohen, Joyce and Moore, Ian N and Patel, Nita and Guebre-Xabier, Mimi and Smith, Gale and Glenn, Greg and Kozlowski, Pamela A and Alter, Galit and Ahmed, Rafi and Suthar, Mehul S and Amara, Rama Rao},
  title = {Efficacy of mRNA-1273 and Novavax ancestral or BA.1 spike booster vaccines against SARS-CoV-2 BA.5 infection in nonhuman primates},
  journal = {Science Immunology},
  year = {2023},
  doi = {10.1126/sciimmunol.adg7015}
}
Kostenlos starten →